Heimbach Julie K, Gores Gregory J, Haddock Michael G, Alberts Steven R, Nyberg Scott L, Ishitani Michael B, Rosen Charles B
William J von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Semin Liver Dis. 2004 May;24(2):201-7. doi: 10.1055/s-2004-828896.
Patients with unresectable, stage I and II perihilar cholangiocarcinoma were treated with neoadjuvant external beam irradiation, brachytherapy, and 5-fluorouracil and/or oral capecitabine prior to liver transplantation. Fifty-six patients underwent treatment between 1993 and 2003. Four patients died and 4 had disease progression prior to completion of neoadjuvant therapy. Forty-eight patients underwent operative staging and 14 had findings precluding transplantation. Twenty-eight patients underwent transplantation and 6 patients are awaiting transplantation. Three patients died from perioperative complications, and 4 developed recurrent disease 22 to 63 months after transplantation. Actuarial patient survival was 54% at 5 years for all 56 patients, 64% for 48 operatively staged patients, and 84% for 34 patients with negative staging operations. Actuarial survival was 88% at 1 year and 82 % 5 years after transplantation. Neoadjuvant chemoradiotherapy with liver transplantation achieves excellent results for patients with localized, regional lymph node negative, hilar cholangiocarcinoma.
不可切除的I期和II期肝门部胆管癌患者在肝移植前接受新辅助外照射、近距离放疗以及5-氟尿嘧啶和/或口服卡培他滨治疗。1993年至2003年间有56例患者接受了治疗。4例患者在新辅助治疗完成前死亡,4例出现疾病进展。48例患者接受了手术分期,14例患者的检查结果排除了移植可能性。28例患者接受了移植,6例患者正在等待移植。3例患者死于围手术期并发症,4例患者在移植后22至63个月出现疾病复发。56例患者的5年总生存率为54%,48例接受手术分期患者的5年总生存率为64%,34例分期手术阴性患者的5年总生存率为84%。移植后1年的生存率为88%,5年生存率为82%。对于局限性、区域淋巴结阴性的肝门部胆管癌患者,新辅助放化疗联合肝移植可取得优异疗效。